Cystatin C and frailty in older men
- PMID: 24001352
- PMCID: PMC3773269
- DOI: 10.1111/jgs.12413
Cystatin C and frailty in older men
Abstract
Objectives: To determine whether higher cystatin C would be associated with greater frailty in men aged 65 and older.
Design: Cross-sectional cohort study.
Setting: Six U.S. sites.
Participants: A random sample of community-dwelling men aged 65 and older enrolled in the Osteoporotic Fractures in Men (MrOS) Study (mean age 73.8; 9.8% frail and 47.2% intermediate frailty; N = 1,602).
Measurements: Serum cystatin C, creatinine, and frailty were measured. Frailty was analyzed as an ordinal outcome of robust, intermediate frailty, and frail using a multinomial logistic regression model, and the base model was adjusted for age, race, and clinical site.
Results: Higher cystatin C was associated with seven times greater odds of being frail than being robust (odds ratio (OR) quartile 4 vs 1 = 7.12, 95% confidence interval (CI) = 3.76-13.46) and 2.4 times greater odds of intermediate frailty than robust (OR quartile 4 vs 1 = 2.38, 95% CI = 1.70-3.32). The association was attenuated but persisted after adjusting for multiple possible confounders. In contrast, neither higher serum creatinine (OR quartile 4 vs 1 = 1.36, 95% CI = 0.78-2.40) nor lower creatinine-based estimated glomerular filtration rate (OR quartile 4 vs 1 = 1.01, 95% CI = 0.54-1.87) was associated in a graded manner with greater odds of frailty.
Conclusion: Higher cystatin C, but not creatinine-based measures, was associated with greater odds of frailty in this cohort of older men.
Keywords: creatinine; cystatin C; elderly; frailty; kidney function.
© 2013, Copyright the Authors Journal compilation © 2013, The American Geriatrics Society.
Conflict of interest statement
Drs. Orwoll and Ensrud have received grant support from the NIH (and supporting agencies) grant as listed under Funding Sources on the title page. Dr. Ensrud also serves as a consultant for Merck Sharpe & Dohme on a Data Monitoring Committee.
References
-
- Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047. - PubMed
-
- Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–M156. - PubMed
-
- Walston J, Mcburnie MA, Newman A, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: Results from the Cardiovascular Health Study. Arch Intern Med. 2002;162:2333–2341. - PubMed
-
- Bandeen-Roche K, Xue QL, Ferrucci L, et al. Phenotype of frailty: characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci. 2006;61:262–266. - PubMed
-
- Boyd CM, Xue QL, Simpson CF, et al. Frailty, hospitalization, and progression of disability in a cohort of disabled older women. Am J Med. 2005;118:1225–1231. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 AR45632/AR/NIAMS NIH HHS/United States
- U01 AR45614/AR/NIAMS NIH HHS/United States
- U01 AR045654/AR/NIAMS NIH HHS/United States
- U01-AG027810/AG/NIA NIH HHS/United States
- U01 AR045583/AR/NIAMS NIH HHS/United States
- U01 AR45583/AR/NIAMS NIH HHS/United States
- U01AR45647/AR/NIAMS NIH HHS/United States
- U01 AR045632/AR/NIAMS NIH HHS/United States
- U01 AR045614/AR/NIAMS NIH HHS/United States
- U01 AR45654/AR/NIAMS NIH HHS/United States
- U01 AR045647/AR/NIAMS NIH HHS/United States
- U01 AR45580/AR/NIAMS NIH HHS/United States
- U01 AG027810/AG/NIA NIH HHS/United States
- UL1 RR024140/RR/NCRR NIH HHS/United States
- U01 AR045580/AR/NIAMS NIH HHS/United States
- U01 AG18197/AG/NIA NIH HHS/United States
- U01 AG018197/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
